http://www.news-medical.net/news/201...ing-round.aspx

Soccertese
I'm confused. I thought the only continuous levodopa delivery method of treatment was Duodopa, a gel paste delivered directly into the duodenum bypassing the stomach via a pump ( much like an insulin pump). I am assuming this gel does not need carbidopa since nausea should not be an issue. Duodopa has been approved and used successfully in Europe for several years.

This article describes another product in the pipeline - one of which I was unfamiliar. This appears to be levodopa in liquid? form but delivered with a patch/pump subcutaneously. And this treatment contains carbidopa. I wonder where this pump is worn ( on what part of the body) that requires the addition of carbidopa. This one has just entered phase II following a successful phase I, which is the safety phase.

Does anyone have a contact for the latter treatment? It's called NDO612 (I think!)
Peggy


Or am I just super mixed up about this???

[QUOTE=pegleg;1091486]Soccertese
I'm confused. I thought the only continuous levodopa delivery method of treatment was Duodopa, a gel paste delivered directly into the duodenum bypassing the stomach via a pump ( much like an insulin pump). I am assuming this gel does not need carbidopa since nausea should not be an issue. Duodopa has been approved and used successfully in Europe for several years.

This article describes another product in the pipeline - one of which I was unfamiliar. This appears to be levodopa in liquid? form but delivered with a patch/pump subcutaneously. And this treatment contains carbidopa. I wonder where this pump is worn ( on what part of the body) that requires the addition of carbidopa. This one has just entered phase II following a successful phase I, which is the safety phase.

Does anyone have a contact for the latter treatment? It's called NDO612 (I think!)
Peggy
QUOTE]

Yes, Peg, NeuroDerm is in Phase II research for a liquid formulation of levodopa/carbidopa. They have received some funding for their research from MJFF. The formula allows for a steady fixed dose throughout the day and can even have day and night settings. The phase I and early phase II results were successful in showing stable blood plasma levels. There are actually four different versions being tested right now. ND0612L is being tested for moderate stage PD. There are two different delivery methods being tested. One is via a small belt-pump which is very similar to an insulin pump. There is a little tube that goes to a patch for subcutaneous delivery. The second verision is more interesting. It is a patch-pump that delivers subcutaneously. The patch has a resevoir for 24 hours of drug and can also be set for day and night dosage.

NDO612H, designed for severe PD, is a high dose LD/CD and is delivered through the insulin-like small pump. Finally, ND0680 is being tested for very severe PWP who require extemely high doses of LD/CD. Their goal is to make this an improved, next generation alternative to Duodopa. As you can tell, if approved, they would all be significantly less invasive than Duodopa and have less side effects. No surgery, no site infections.

On a side note, the company is also testing ND0701, which is a continuously administered form of apomorphine.

Gary

I knew that I wanted to wait and not do Duodopa for some reason! This sounds very promising and right for my circumstances. I appreciate you taking the time to reply. Keeping my fingers crossed.
Peg

NeuroDerm will release top-line results for ND0612L from a phase II study in patients with moderate Parkinson's patients, and preliminary interim results from a phase IIA study of ND0612H and ND0612L in advanced Parkinson's patients, at The Michael J. Fox Foundation's 2014 Parkinson's Disease Therapeutics Conference, on October 29th in New York, NY.

As Duodopa still has not yet received US FDA approval, NeuroDerm's ND0612L may make it obsolete before it ever hits the market.